Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154606 | 0.88 | MAPT (0.66) | MAPTSMN1; SMN2ALDH1A1GAAKMT2A | |
| Nitric Acid SCHEMBL2076208 | 0.85 | ALDH1A1 (0.52) | MAPTSMN1; SMN2ALDH1A1KMT2ANPC1 | |
| Nitric Acid SCHEMBL9982936 | 0.81 | LMNA (0.49) | MAPTSMN1; SMN2ALDH1A1KMT2ANPC1 | |
| Nitric Acid SCHEMBL2073717 | 0.80 | KMT2A (0.50) | MAPTSMN1; SMN2ALDH1A1KMT2ARAB9A | |
| Nitric Acid SCHEMBL2852035 | 0.80 | PEPD (0.52) | MAPTALDH1A1GAAKMT2ALMNA | |
| Nitric Acid SCHEMBL2544082 | 0.78 | NPC1 (0.53) | MAPTALDH1A1GAAKMT2ANPC1 | |
| Nitric Acid SCHEMBL4613840 | 0.78 | ALDH1A1 (0.53) | MAPTSMN1; SMN2ALDH1A1GAAKMT2A | |
| Nitric Acid SCHEMBL1833737 | 0.78 | MEN1 (0.46) | MAPTSMN1; SMN2ALDH1A1KMT2ANPC1 | |
| Nitric Acid SCHEMBL1184061 | 0.78 | CA1 (0.44) | KMT2ATP53CA9CA1CA2 | |
| Nitric Acid SCHEMBL3860512 | 0.78 | KMT2A (0.59) | MAPTSMN1; SMN2ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| EP-1641805-B1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROTEIN KINASES | CYCLACEL LTD (GB) | 2010-01-13 | — | — | EP | disclosed |
| US-7576091-B2 | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | CYCLACEL LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| CN-100500663-C | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl) -n-phenylamines as antiproliferative compounds | CYCLACEL LTD (GB) | 2009-06-17 | — | — | CN | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| CN-100425239-C | Therapeutic applications of 2-substituted 4-heteroarylpyrimidines | CYCLACEL LTD (GB) | 2008-10-15 | — | — | CN | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7427627-B2 | N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2008-09-23 | — | — | US | disclosed |
| CN-100404540-C | Thiazolo-, oxazolo-and imidazoquinazoline compounds which inhibit protein kinases | CYCLACEL LTD (GB) | 2008-07-23 | — | — | CN | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| WO-2005005438-A1 | THIAZOLO-, OXAZALO AND IMIDAZOLO-QUINAZOLINE COMPOUNDS CAPABLE OF INHIBITING PROT EIN KINASES | CYCLACEL LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CYCLACEL LIMITED (GB) | 2004-12-23 | — | — | US | disclosed |
| WO-2004056368-A1 | THERAPEUTIC APPLICATIONS OF 2-SUBSTITUTED 4-HETEROARYLRYRIMIDINES | CYCLACEL LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1430051-A1 | N-(4-(4-METHYLTHIAZOL-5-YL)PYRIMIDIN-2-YL)-N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | Cyclacel Limited (GB) | 2004-06-23 | — | — | EP | disclosed |
| WO-2004043953-A1 | PYRIMIDINE COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | disclosed |
| WO-2003029248-A1 | N-(4-(4-METHYLTHIAZOL-5-YL) PYRIMIDIN-2-YL) -N-PHENYLAMINES AS ANTIPROLIFERATIVE COMPOUNDS | CYCLACEL LIMITED (GB) | 2003-04-10 | — | — | WO | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259894-A1 | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds | CDK4, CDK2, CDKL4 | MAPT 1209/4885SMN1; SMN2 2905/4885ALDH1A1 2719/4885 |
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | MAPT 1954/4885SMN1; SMN2 2791/4885ALDH1A1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.